Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Lioger

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Allergy|January 6, 2025
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter CohortGuillaume Lefèvre, Séverine Bleuse, Mathieu Puyade, et al.
RMD Open|June 15, 2023
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective studyArsène Mekinian, Lucie Biard, Dagna Lorenzo, et al.
Rheumatology (Oxford, England)|August 14, 2025
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective studyArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 24, 2025
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic SyndromeRomain Stammler, Alexandre Vallée, Julien Rohmer, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Allergy|January 6, 2025
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter CohortGuillaume Lefèvre, Séverine Bleuse, Mathieu Puyade, et al.
RMD Open|June 15, 2023
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective studyArsène Mekinian, Lucie Biard, Dagna Lorenzo, et al.
Rheumatology (Oxford, England)|August 14, 2025
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective studyArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 24, 2025
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic SyndromeRomain Stammler, Alexandre Vallée, Julien Rohmer, et al.
Pageof 6